Dataset Information


Combination therapy with polymyxin B and netropsin against clinical isolates of multidrug-resistant Acinetobacter baumannii.

ABSTRACT: Polymyxins are last-resort antibiotics for treating infections of Gram-negative bacteria. The recent emergence of polymyxin-resistant bacteria, however, urgently demands clinical optimisation of polymyxin use to minimise further evolution of resistance. In this study we developed a novel combination therapy using minimal concentrations of polymyxin B. After large-scale screening of Streptomyces secondary metabolites, we identified a reliable polymixin synergist and confirmed as netropsin using high-pressure liquid chromatography, nuclear magnetic resonance, and mass spectrometry followed by in vitro assays using various Gram-negative pathogenic bacteria. To evaluate the effectiveness of combining polymixin B and netropsin in vivo, we performed survival analysis on greater wax moth Galleria mellonella infected with colistin-resistant clinical Acinetobacter baumannii isolates as well as Escherichia coli, Shigella flexineri, Salmonella typhimuruim, and Pseudomonas aeruginosa. The survival of infected G. mellonella was significantly higher when treated with polymyxin B and netropsin in combination than when treated with polymyxin B or netropsin alone. We propose a netropsin combination therapy that minimises the use of polymyxin B when treating infections with multidrug resistant Gram-negative bacteria.


PROVIDER: S-EPMC4910107 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2009-01-01 | S-EPMC2821790 | BioStudies
1000-01-01 | S-EPMC4033650 | BioStudies
1000-01-01 | S-EPMC3294921 | BioStudies
2017-01-01 | S-EPMC5955700 | BioStudies
2021-01-01 | S-EPMC7917812 | BioStudies
2017-01-01 | S-EPMC5515593 | BioStudies
2020-01-01 | S-EPMC7552488 | BioStudies
2009-01-01 | S-EPMC2772482 | BioStudies
2016-01-01 | S-EPMC4774972 | BioStudies
2014-01-01 | S-EPMC4244539 | BioStudies